Study of AO-252 for advanced solid tumors with or without brain metastases
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental oral pill (AO-252) that targets a protein called TACC3 in advanced solid tumors, including those that have spread to the brain. It is for people whose cancer has a specific genetic change (TP53 mutation) or who have prostate cancer, and who have already tried other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced (spread or not removable by surgery) and have a TP53 gene mutation (or loss) — except for prostate cancer, which doesn't need this mutation.
- You must have tried at least one prior cancer treatment that didn't work or stopped working (melanoma is not included).
- If you have prostate cancer, it must be castration-resistant and you must have progressed on at least one hormone therapy or chemotherapy.
- If you have brain metastases, they must be small (0.5 to 3 cm) and not needing immediate treatment.
- You must have adequate organ function (kidney, liver, bone marrow) and be generally well enough to do daily activities.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new tablet, DC50292A, for people whose cancer has an MTAP gene deletion. It is for patients whose cancer has spread or returned and who have not had success with other treatments.
This Phase 1 study tests AMT-253, an experimental drug, in people with advanced solid cancers that have grown despite prior treatment (or where standard options were not tolerated). The goal is to find a safe dose and learn how the drug affects the cancer.
This trial tests a new pill called ACC-1898 for adults with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
This early-phase study tests ATG-022 in adults with advanced or metastatic solid cancers that have progressed on standard treatment, cannot use standard treatment, or have no standard option. It may help by targeting cancer cells differently, and participation includes close monitoring and likely a biopsy.
This study tests a new targeted drug called ACR-2316 for people with specific advanced solid tumors that have already been treated but are no longer responding. It aims to see how well the drug works and how safe it is, while looking for a tumor that has certain markers (like a protein or genetic change) that may make the drug more effective.
This trial tests a new combination treatment (HC010) for people with advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Hear when a new Brain Metastases From Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.